PNTG Stock Forecast & Price Target

Pennant Gr is positioned favorably because it continues to post strong organic growth in its higher-margin home health and hospice core, with Q3:26 revenue of $239.8M, adjusted EPS of $0.35, and adjusted EBITDA of $24.7M, while same-store Medicare home health admissions rose 12.0% and hospice same-store ADC grew 13.0%. Its outlook is also supported by improving reimbursement conditions, with management maintaining FY2026 guidance of $1.34-$1.41 for adjusted EPS and $94.4M-$98.0M for adjusted EBITDA, implying confidence in ongoing margin conversion from volume growth. Longer term, the company’s clean balance sheet, strong M&A track record, and progress integrating the Southeast assets should expand consolidation opportunities and unlock additional margin upside across both home-based care and senior living.

Pennant Gr is viewed negatively because its home health and hospice operations are heavily reliant on Medicare and Medicaid reimbursement, leaving results exposed to government funding pressure, audits, and other regulatory investigations. The company also faces meaningful execution risk from its rapid pace of expansion, as integration headwinds could force it to halt incremental M&A while new and transitioning assets fail to turn around as expected. In senior living, a high fixed-cost structure, labor-market strain, and supply headwinds could compress margins and occupancy, with the downside scenario implying FY27E EBITDAR 5% below estimate and a 10.7x valuation multiple.